The stock price of GlucoTrack Inc (NASDAQ: GCTK) has dropped by -14.88 compared to previous close of 0.20. Despite this, the company has seen a fall of -35.37% in its stock price over the last five trading days. globenewswire.com reported 2025-03-31 that Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company.
Is It Worth Investing in GlucoTrack Inc (NASDAQ: GCTK) Right Now?
The 36-month beta value for GCTK is also noteworthy at -0.01.
The public float for GCTK is 10.17M, and at present, short sellers hold a 2.79% of that float. The average trading volume of GCTK on April 01, 2025 was 6.25M shares.
GCTK’s Market Performance
GCTK stock saw a decrease of -35.37% in the past week, with a monthly decline of -51.69% and a quarterly a decrease of -96.70%. The volatility ratio for the week is 16.52%, and the volatility levels for the last 30 days are 20.96% for GlucoTrack Inc (GCTK). The simple moving average for the past 20 days is -45.29% for GCTK’s stock, with a -99.23% simple moving average for the past 200 days.
GCTK Trading at -75.11% from the 50-Day Moving Average
After a stumble in the market that brought GCTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.82% of loss for the given period.
Volatility was left at 20.96%, however, over the last 30 days, the volatility rate increased by 16.52%, as shares sank -48.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -88.18% lower at present.
During the last 5 trading sessions, GCTK fell by -35.37%, which changed the moving average for the period of 200-days by -99.66% in comparison to the 20-day moving average, which settled at $0.3189. In addition, GlucoTrack Inc saw -97.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GCTK starting from SYCOFF DREW, who purchase 182,540 shares at the price of $1.26 back on Apr 22 ’24. After this action, SYCOFF DREW now owns 2,951,258 shares of GlucoTrack Inc, valued at $230,000 using the latest closing price.
Stock Fundamentals for GCTK
Current profitability levels for the company are sitting at:
- -157.33 for the present operating margin
- 0.21 for the gross margin
The net margin for GlucoTrack Inc stands at -355.12. The total capital return value is set at 1.75. Equity return is now at value -1943.32, with -371.90 for asset returns.
Based on GlucoTrack Inc (GCTK), the company’s capital structure generated -1.28 points at debt to capital in total, while cash flow to debt ratio is standing at -5.06.
When we switch over and look at the enterprise to sales, we see a ratio of 88.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.14.
Conclusion
In summary, GlucoTrack Inc (GCTK) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
